Spravato is just the beginning in a new wave of depression meds
When Dr. Husseini Manji was developing the first-in-class depression medication Spravato at Johnson & Johnson he encountered plenty of naysayers. “A lot of people didn’t think it would work,” the adjunct professor of psychiatry at Yale University and …